Please assess the completion status of the following clinical trial:

Trial Title: Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 40 years of age at the time of hospital admission~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to the International Statistical Classification of Diseases and Related Health Problems Version 10 (ICD-10) established by the Health Care Protocol of the Health Secretariat of Federal District (SES/DF), with the following codes:~  * J41.0 - Simple chronic bronchitis~ * J41.1 - Mucopurulent chronic bronchitis~ * J41.8 - Mixed simple and mucopurulent chronic bronchitis~ * J42 - Unspecified chronic bronchitis~ * J43.1 - Panlobular emphysema~ * J43.2 - Centrilobular emphysema~ * J43.8 - Other emphysema~ * J43.9 - Emphysema, unspecified~ * J44.0 - Chronic obstructive pulmonary disease with acute lower respiratory infection~ * J44.1 - Chronic obstructive pulmonary disease with acute exacerbation, unspecified~ * J44.8 - Other specified chronic obstructive pulmonary disease~ * J44.9 - Chronic obstructive pulmonary disease, unspecified~Exclusion Criteria:~* Patients younger than 40 yeas of age at the time of hospital admission

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients diagnosed with COPD, admitted to the hospital with acute exacerbations (Type: None): Patients over 40 years of age, diagnosed with Chronic Obstructive Pulmonary Disease (COPD), admitted to the hospital with acute exacerbations as recorded in the DATASUS (Unified Health Brazilian System Informatics Department (in Portuguese) between August 2017 and July 2019. Patients were treated with either Tiotropium bromide in soft mist inhaler (SPIRIVA® RESPIMAT®) or with Glycopyrronium bromide in dry powder inhaler (Seebri® Breezhaler®) as part of the treatment plan for Chronic Obstructive Pulmonary Disease (COPD) defined by the Health State Secretariat of Distrito Federal (DF) in Brazil.

Based on this trial design, predict the completion outcome and termination type (if applicable).